A Multicenter Phase II Trial of Gemcitabine Plus Oxaliplatin in Unresectable Gallbladder Cancer

Sang Myung Woo*,†, Sang Hyub Lee*,‡, Ji Won Yoo*, Ki Young Yang*, Jung Gun Seo*, Joo Kyung Park*, Jin-Hyeok Hwang†, Woo Jin Lee†, Ji Kon Ryu*, Yong-Tae Kim*, and Yong Bum Yoon*

*Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul. †Center for Liver Cancer, National Cancer Center, Goyang, and ‡Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea

Background/Aims: No standard chemotherapy has been established for advanced gallbladder cancer. The authors studied the activity and tolerability of a gemcitabine and oxaliplatin (GEMOX) combination in unresectable gallbladder cancer (GBC). Methods: Adult patients with pathologically confirmed unresectable GBC were prospectively recruited at three centers. No patient had received prior chemotherapy or radiotherapy. Patients received cycles of gemcitabine at 1,000 mg/m² on day 1, followed by oxaliplatin at 100 mg/m² on day 2, every 2 weeks. The primary study endpoint was time to progression. Results: Forty patients with unresectable GBC were enrolled. The median age was 60 years (range, 38 to 79 years). All patients showed good performance status. Of the 33 analyzable patients, 12 achieved partial response (36%), 17 stable disease (52%), and four progressive disease (12%). No patient achieved a complete response. The tumor control rate was 88%. At a median follow-up of 6.8 months, the median time to progression was 5.3 months (95% confidence interval [CI], 3.7 to 6.9), and median overall survival was 6.8 months (95% CI, 6.1 to 7.5). Nine of the 40 patients (23%) experienced at least a grade-3 adverse event, but no patient experienced a grade-4 adverse event. Conclusions: GEMOX combination therapy is a feasible option and is well tolerated in unresectable GBC. (Gut Liver 2013;7:594-598)

Key Words: Gallbladder neoplasms; Gemcitabine; Oxaliplatin

INTRODUCTION

Biliary tract cancers comprise intrahepatic cholangiocarcinoma (CC), extrahepatic CC, gallbladder cancer (GBC), and papilla of Vater cancer. Of these cancers, GBC shows marked geographic and ethnic variations in incidence.†‡ GBC is an uncommon disease in the West, but its incidence is relatively high in East Asia, for example, it accounts for 1.3% of all malignancies in South Korea.† Early metastasis, late diagnosis, and frequent recurrence after resection are important features of this disease, and 5-year survival for GBC patients is less than 10%.†‡§

Although chemotherapy for overall biliary tract cancer has been reported to be beneficial over best supportive care,† no standard chemotherapeutic regimen has been established. In a recent multicenter phase III trial, it was concluded that the gemcitabine-cisplatin combination is superior to gemcitabine alone in advanced biliary tract cancer, and the subgroup analysis conducted showed that combination therapy can also prolong the survival of GBC patients. However, no phase III trial has been conducted exclusively in GBC patients. In the majority of studies, cohorts were composed of highly heterogeneous patient groups containing intrahepatic and extrahepatic CC, GBC, papilla of Vater cancer, and even pancreatic cancer. However, it is evident that GBC differs from other bile duct cancers at both the molecular and clinical levels.†§ One pooled analysis of 104 chemotherapy trials in biliary tract cancer revealed that response rates (RRs) of GBC are higher than those of CC (34.4% vs 20.2%, respectively), but that GBC patients have shorter overall survival (OS) than CC patients (7.2 months vs 9.3 months, respectively).†‡

Furthermore, the tumor biology of GBC is likely to differ by ethnicity and etiology. Eighty percent of GBC cases are associated with a GB stone in the West, whereas anomalous union of the pancreaticobiliary duct is more frequently associated with GBC in East Asia.†‡§ In addition, genetic alterations in GBC are...
dependent on its etiology.17

Despite the lack of a randomized controlled study, single
gemcitabine has been used as a chemotherapeutic agent in
GBC for a decade, though results have been unremarkable. Five
phase II studies18-22 that evaluated the activity of gemcitabine
and oxaliplatin (GEMOX) in advanced biliary tract cancer or
GBC, concluded that gemcitabine-oxaliplatin is beneficial and
has tolerable adverse effects in biliary tract cancer and in GBC.
Recently, a phase III study19 of GEMOX with or without erlo-
tinib in advanced biliary tract cancer showed that RR and me-
dian OS for gemcitabine plus oxaliplatin group were 16% and
9.5 months, respectively. The aim of the present study was to
evaluate gemcitabine-oxaliplatin activity and tolerability exclu-
sively in patients with GBC in Korea, where the etiology of the
disease differs appreciably from that found in the West. When
this study was initiated, no information was available regarding
the efficacy of gemcitabine-oxaliplatin in GBC.

MATERIALS AND METHODS

1. Eligibility criteria

The eligibility criteria applied were as follows. An age of 18
to 80 years with histologically confirmed, locally advanced or
metastatic GBC. In addition, patients had not received prior che-
mo or radiotherapy, had a WHO performance status (PS)
of 0 to 2, no central nervous system metastases, no uncontrolled
infection, a life expectancy of >3 months, adequate hematologi-
cal parameters (neutrophils ≥1,500/mm3, platelets ≥100,000/
mm3), and adequate renal and liver functions (serum creatinine
<1.5 of the upper limit of normal [ULN] and bilirubin <2.5
ULN). Written informed consent was obtained from each pa-
tient before enrollment and the study protocol was approved by
the institutional review boards of three centers (Seoul National
University Hospital, Seoul; the National Cancer Center, Goyang;
and Seoul National University Bundang Hospital, Seongnam,
Korea).

2. Pretreatment evaluation

Baseline biological analyses (peripheral blood cell count, se-
rum creatinine, bilirubin, aspartate aminotransferase, alanine
aminotransferase, alkaline phosphatase, and CA19-9 level) were
performed within 1 week of the first cycle and tumor size was
assessed by computer tomography (CT) less than 3 weeks be-
fore starting the first cycle. A physical examination, complete
peripheral blood cell count analysis, and chemical tests were
performed within 3 days of starting each cycle.

3. Treatment

All 40 patients were treated using the GEMOX regimen,
which comprised gemcitabine (Yuhan Co., Ltd., Seoul, Korea)
1,000 mg/m2 as a 10 mg/m2/min (100 minutes) infusion on day
1, followed by oxaliplatin (Yuhan Co., Ltd.) 100 mg/m2 as a
2-hour infusion on day 2. Treatment was repeated fortnightly.
If a nonneurological toxicity occurred of severity greater than
grade 2 according to the National Cancer Institute Common
Toxicity Criteria (NCI CTC) version 3.0, subsequent cycles were
administered after recovery and the gemcitabine dose was de-
creased to 800 mg/m2 (given as an 80-minute infusion) and
oxaliplatin to 85 mg/m2. Oxaliplatin was discontinued when a
cumulative peripheral sensory neuropathy of NCI CTC grade 3
occurred; affected patients received only gemcitabine thereafter.
When laryngopharyngeal dysesthesia occurred, the duration of
oxaliplatin infusion was prolonged to 6 hours, but disconti-
ued if symptoms recurred during subsequent cycles. Patients
received GEMOX until there was evidence of disease progres-
sion or unacceptable toxicity or they refused further treatment.
A chemotherapy delay was defined as one of more than 7 days
after the scheduled date.

4. Assessment of efficacy

The primary end point of this study was time to progression
(TTP) and secondary endpoints were safety, RR, and OS. Tumor
evaluations were performed every 2 months (every four cycles)
during therapy using the Response Evaluation Criteria for Solid
Tumors,23 or earlier when clinically indicated. TTP was defined
as the time from first day of treatment until evidence of clinical
progression or tumor progression by CT. OS was defined as time
from first day of treatment until death.

5. Statistical analysis

Sample size was calculated on the assumptions that TTP was
3 months for 5-fluorouracil (FU) and that gemcitabine plus ox-
aliplatin would result in an improvement to 6 months. A one-
sided significance test and a 5% type-I error, and a statistical
power of 80% were chosen. Estimating a dropout rate of 10%,
at least a total of 35 patients were planned to be accrued for this
study. An accrual period of 24 months and a follow-up period
of 12 months required the inclusion of 35 patients. TTP and OS
data were analyzed using the Kaplan-Meier method.

RESULTS

1. Patient characteristics

Forty patients (16 men and 24 women) with unresectable
GBC were enrolled from May 2006 to October 2007 (Table 1).
The date cutoff for data analysis was October 7, 2008. Median
patient age was 60 years (range, 38 to 79 years) and all had a
good PS. All patients had locally advanced disease with/without
metastasis and no patient had received prior chemotherapy or
radiotherapy for GBC.

2. Drug delivery

Patients received a total of 257 cycles of chemotherapy (a
median of 5.5 cycles [range, 1 to 12 cycles] per patient). Thirty
patients (75%) completed at least four cycles of therapy. The mean cumulative doses of GEMOX received were 9,951 mg (±6,425) and 997 mg (±616), respectively. The average relative dose intensities of GEMOX were 93.2% and 91.6%, respectively. All 257 cycles were administered as scheduled. Gemcitabine dosage was reduced by 25% for one cycle (0.3%) in one patient.

Oxaliplatin dosage was reduced for nine cycles (2.7%) in six patients (a 25% reduction for two cycles and by discontinuation for seven cycles).

3. Efficacy and survival

Of the 40 patients, 33 were analyzed for tumor response. Four patients dropped out from the study because of cholangiohepatitis and three refused further chemotherapy after two cycles of chemotherapy without any apparent toxic effect or evidence of disease progression. Of these 33 patients, none achieved complete response (CR) and 12 achieved partial response (PR) (Table 2). Seventeen patients had stable disease (SD) and four progressive diseases. The tumor RR was 36% and the tumor control rate was 88%. Median time to response (CR/PR/SD) was 8.0 weeks (range, 1.7 to 26.7 weeks) from start of therapy. The overall median response-duration was 4.3 months (range, 0.7 to 15.2 months) and the median response-duration of patients that achieved PR was 6.6 months (range, 2.3 to 12.4 months). During a median follow-up of 6.8 months, median TTP was 5.3 months.

Table 1. Characteristics of Patients

| Characteristic                  | Value   |
|---------------------------------|---------|
| Total                           | 40 (100)|
| Median age, yr                  | 60 (38-79)|
| Sex                             |         |
| Male                            | 16 (40) |
| Female                          | 24 (60) |
| Extension of disease at study entry |        |
| Locally advanced                | 10 (25) |
| Metastatic                      | 30 (75) |
| Prior therapy                   | 0 (0)   |

Data are presented as number (%) or median (range).

Table 2. Best Response according to RECIST Criteria

| Best response on treatment       | No. (%) |
|----------------------------------|---------|
| Total                            | 33 (100)|
| Complete response (CR)           | 0 (0)   |
| Partial response                 | 12 (36) |
| Stable disease (SD)              | 17 (52) |
| Progressive disease              | 4 (12)  |
| Response rate (RR)               | 12 (36) |
| Tumor control rate (CR+RR+SD)    | 29 (88) |

RECIST, Response Evaluation Criteria for Solid Tumor.

Fig. 1. Kaplan-Meier survival curve for time to progression (n=40).

Fig. 2. Kaplan-Meier survival curve for overall survival (n=40). (A) Overall survival. (B) Survival curves according to response. CI, confidence interval.
months (95% confidence interval [CI], 3.7 to 6.9) (Fig. 1). For these 33 patients, median OS was 6.8 months (95% CI, 6.1 to 7.5) (Fig. 2A), and the 1-year survival rate was 25.0%. Median TTPs for responders and for those with disease stabilization were 10.4 months (95% CI, 6.7 to 14.8) and 5.3 months (95% CI, 3.5 to 7.1), respectively, and median OSs for these two patient group were 11.4 months (95% CI, 6.0 to 16.8) and 7.0 months (95% CI, 3.9 to 10.0), respectively. Median survival of patients who achieved PR was longer than that of nonresponders (SD or PD) (11.4 months vs 5.3 months; p<0.05) (Fig. 2B). Gender, age, and initial disease presentation patterns did not affect OS or TTP.

4. Toxic effects

All 40 patients were analyzed for toxic effects (Table 3). Ten of the 40 (25%) experienced at least a grade 3 adverse event. Adverse events were predominantly grade 1 or 2. Grade 3 hematologic toxic effects were uncommon. The most common grade 3/4 toxicity was neutropenia in three patients (1.2% per cycle). Two patients experienced febrile neutropenia and required brief episodes of hospitalization and empiric antibiotic administration. Grade 3/4 nonhematologic toxic effects were nausea/vomiting in four patients (10%). There were no treatment-related deaths. Cholangiohepatitis without neutropenia developed in four patients after the first or second cycle of chemotherapy. Ten of 40 patients (25%) experienced at least a grade 3 adverse event. NCI CTC, National Cancer Institute Common Toxicity Criteria. Data are presented as number (%).

Table 3. Grade-3 or -4 NCI CTC Toxicity per Cycle and per Patient

| Parameter          | Patients (n=40)* | Cycles (n=257) |
|--------------------|-----------------|----------------|
|                    | Grade 3 | Grade 4 | Grade 3 | Grade 4 |
| Neutropenia        | 3 (7.5) | -       | 4 (1.6) | -       |
| Fever neutropenia  | 2 (5)   | -       | 3 (1.2) | -       |
| Thrombocytopenia   | -       | 1 (2.5) | -       | 1 (0.4) |
| Pulmonary embolism | -       | 1 (2.5) | -       | 1 (0.4) |
| Anemia             | 2 (5)   | -       | 3 (1.2) | -       |
| Nausea/Vomiting    | 4 (10)  | -       | 5 (1.9) | -       |
| Diarrhea           | 1 (2.5) | -       | 2 (0.8) | -       |

Data are presented as number (%). NCI CTC, National Cancer Institute Common Toxicity Criteria. *Ten of 40 patients (25%) experienced a grade-3 or -4 adverse event.

DISCUSSION

No standard chemotherapeutic regimen has been established for advanced GBC. Clinical trials on chemotherapies for GBC have not been actively pursued because it is rare in the West, the difficulties of obtaining an adequate biopsy specimen, and high incidences of complications, such as, cholangiohepatitis and jaundice. A pooled analysis of clinical trials showed that the mean number of GBC patients per clinical trial was only 16.7.10

In the present study, we enrolled 40 GBC patients, which is a relatively large number. Gemcitabine-oxaliplatin resulted in a tumor RR of 36% and temporary abrogation of progression in 88%. Median TTP and OS were 5.3 and 6.8 months, respectively. Only five phase II trials have been conducted exclusively in GBC to determine the activities of palliative chemotherapies17,21-24 results are summarized in Table 4 and compared with those of present study. The regimens used in these studies were single gemcitabine, 5 FU-cisplatin, or gemcitabine plus platinum agents. However, Malik’s study22 should be excluded from such comparisons because the patient number was too small and the regime used was heterogeneous. Taking the four remaining studies and the present study, RRs ranged from 21.2% to 36.6% and median OS from 5 to 7.5 months. However, because none of these studies had a control group, it is difficult to determine the merits and demerits of the regimens used. Hematologic and nonhematologic toxicity of grade 3 or 4 occurred more frequently during gemcitabine-cisplatin than gemcitabine-oxaliplatin studies. Sharma et al.17 used a gemcitabine-oxaliplatin combination like the present study, but the doses and schedules used differed. Whereas they infused gemcitabine at 900 mg/m² and oxaliplatin at 80 mg/m² on days 1 and 8 every 3 weeks, we infused gemcitabine at 1,000 mg/m² on day 1 and oxaliplatin at 100 mg/m² on day 2 every 2 weeks. However, incidences of grade 3/4 toxicities were similar in the two studies (22% vs 25%).

In a study by Valle et al.,27 although results were obtained by subgroup analysis of heterogenous biliary cancers rather

Table 4. Results of Phase II Studies Conducted Only on Gallbladder Carcinoma Patients

| Author          | Chemotherapy       | No. of patients | RR, %b | Median OS, mo |
|-----------------|--------------------|-----------------|--------|---------------|
| Gallardo et al. (2001)17 | Gemcitabine       | 26              | 36     | 7.5           |
| Malik et al. (2003)22 | Gemcitabine+cisplatin | 11             | 64     | 10.5          |
| Doval et al. (2004)21 | Gemcitabine+cisplatin | 30             | 36.6   | 4.8           |
| Chatni et al. (2008)24 | 5 FU+cisplatin     | 65              | 33.7   | 5.7           |
| Sharma et al. (2010)17 | Gemcitabine+oxaliplatin | 48             | 21.2   | 7.5           |
| Present study (2012) | Gemcitabine+oxaliplatin | 40             | 36     | 6.8           |

RR, response rate; OS, overall survival.
than by analysis of an exclusive GBC population, gemcitabine-cisplatin was found to be superior to gemcitabine alone in GBC patients, especially when PS was good. In a recent phase trial of GEMOX with or without erlotinib, median progression-free survival for the patients with GBC was 4.0 months, consistent with our data. Our results showed that median time to progression was 5.3 months (95% CI, 3.7 to 6.9) with a median follow-up of 6.8 months. These findings indicate that gemcitabine-cisplatin and gemcitabine-oxaliplatin regimens are suitable for the treatment of advanced GBC. Further studies are needed to address this issue.

The encouraging results obtained in the present study for a gemcitabine-oxaliplatin based combination therapy, and in the previous studies, suggest that gemcitabine plus a platinum agent can be used to manage locally advanced or metastatic GBC. Summarizing, the present study shows that GEMOX chemotherapy is feasible and safe in Korean patients with advanced GBC.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

REFERENCES

1. Misra S, Chaturvedi A, Misra NC, Sharma ID. Carcinoma of the gallbladder. Lancet Oncol 2003;4:167-176.
2. Lazzcano-Ponce EC, Miquel JF, Muñoz N, et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin 2001;51:349-364.
3. Shin HR, Jung KW, Won YJ, Park JG; 139 KCCR-affiliated Hospitals. 2002 Annual report of the Korea Central Cancer Registry: based on registered data from 139 hospitals. Cancer Res Treat 2004;36:103-114.
4. Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer 2006;118:1591-1602.
5. de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med 1999;341:1368-1378.
6. Glimeilius B, Hoffman K, Sjödén PO, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996;7:593-600.
7. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;362:1273-1281.
8. Jarnagin WR, Klimstra DS, Hezel M, et al. Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables, and clinical outcome. J Clin Oncol 2006;24:1152-1160.
9. Yonemoto N, Furuse J, Okusaka T, et al. A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer. Jpn J Clin Oncol 2007;37:843-851.
10. Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 2007;96:896-902.
11. Kimura K, Ohto M, Saisho H, et al. Association of gallbladder carcinoma and anomalous pancreaticobiliary ductal union. Gastroenterology 1985;89:1258-1265.
12. Park YK, Kim SW, Park YH. A clinical study of gallbladder carcinoma. Korean J Gastroenterol 1989;21:113-122.
13. Hanada K, Itoh M, Fujii K, Tsuchida A, Ooishi H, Kajiyama G. K-ras and p53 mutations in stage I gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct. Cancer 1996;77:452-458.
14. Andre T, Tourmiinand C, Rosmorduc O, et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 2004;15:1339-1343.
15. Andre T, Reyes-Vidal JM, Faroux L, et al. Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer 2008;99:862-867.
16. Kim HJ, Lee NS, Lee SC, et al. A phase II study of gemcitabine in combination with oxaliplatin as first-line chemotherapy in patients with inoperable biliary tract cancer. Cancer Chemother Pharmacol 2009;64:371-377.
17. Sharma A, Mohanit B, Raina V, et al. A phase II study of gemcitabine and oxaliplatin (Oxigem) in unresectable gall bladder cancer. Cancer Chemother Pharmacol 2010;65:497-502.
18. Harder J, Riecken B, Kummer O, et al. Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer. Br J Cancer 2006;95:848-852.
19. Lee J, Park SH, Chang HM, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2012;13:181-188.
20. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer. National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
21. Gallardo JO, Rubio B, Fodor M, et al. A phase II study of gemcitabine in gallbladder carcinoma. Ann Oncol 2001;12:1403-1406.
22. Malik IA, Aziz Z, Zaidi SH, Sethuraman G. Gemcitabine and Cisplatin is a highly effective combination chemotherapy in patients with advanced cancer of the gallbladder. Am J Clin Oncol 2003;26:174-177.
23. Doval DC, Sekhon JS, Gupta SK, et al. A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer. Br J Cancer 2004;90:1516-1520.
24. Chatni SS, Sainani RS, Mehta SA, Mohandas KM. Infusion chemotherapy with cisplatinum and fluorouracil in the treatment of locally-advanced and metastatic gallbladder cancer. J Cancer Res Ther 2008;4:151-155.